Effects of compound planting on growth and quality of Salvia miltiorrhiza / 中国中药杂志

The effects of four kinds of different plant populations on the morphology, the dry matter accumulation, active ingredient content and antioxidant activty in vitro of Salvia miltiorrhiza were analyzed by setting up four kinds of mixed planting groups, such as S. miltiorrhiza and Cassia obtusifolia, Capsicum annuum, Perilla frutescens and Zea mays. And through the root isolation treatment, we preliminarily explored the formation mechanism of the four kinds of matching plants of the yield and quality of S. miltiorrhiza, and chose the matching plants suitable for the establishment of the compound population with S. miltiorrhiza,and provided the basis for constructing high efficiency compound planting pattern of S. miltiorrhiza. The results showed that there were significant differences in plant morphology, dry matter accumulation of root, active ingredient content and antioxidant activty in vitro of S. miltiorrhiza in different compound population mixed. The growth and yield of S. miltiorrhiza were unfavorable to the combination planting of Cassia obtusifolia, Z. mays and Salvia miltiorrhiza.The compound planting of P. frutescens and S. miltiorrhiza significantly promoted the growth of S. miltiorrhiza, but significantly reduced the quality of S. miltiorrhiza.The yield and quality of S. miltiorrhiza were significantly improved by the combination of C. annuum and S. miltiorrhiza. Therefore, among the four plants of C. obtusifolia, C. annuum, P. frutescens, and Z. mays, the P. frutescens of Solanaceae is the best matching species for the construction of compound planting group with S. miltiorrhiza.

Efficacy of RCDOP regimen in the treatment of patients with diffuse large B-cell lymphoma / 中华血液学杂志

Objective: To investigate the efficacy of RCDOP (Rituximab, cyclophosphamide, liposome doxorubicin, vincristine and prednisone) regimen in patients with de novo diffuse large B-cell lymphoma (DLBCL), especially in those patients with multiple extra-nodal involvement or Bulky diseases. Methods: A total of 87 newly diagnosed DLBCL patients who received RCDOP regimen from October 2012 to October 2017 were enrolled into this study. Survival functions were estimated using the Kaplan-Meier method and compared by the log-rank test, and χ(2) tests were used for categorical data. Results: Among the 87 DLBCL patients treated with RCDOP regimen, 81 patients achieved complete remission (CR) or partial remission (PR), with ORR as 93.1%. Patients were further classified into groups, according to the risk factors, such as IPI scores, multiple extra-nodal involvement, bulky disease, age>60, tumor Ki-67>80%, elevated serum LDH level and advanced Ann Arbor stage. The progression-free survival (PFS, P=0.084) and overall survival (OS, P=0.515) had no statistical difference among the IPI low risk (0-1 score) group, intermediate risk (2-3 scores) group and high risk (4-5 scores) group. Similarly, no statistical difference were fou nd in PFS and OS of patients with extra-nodal involvements ≥2 (P=0.303 and P=0.624), with bulky disease (P=0.518 and P=0.466), with age>60 (P=0.600 and P=0.183), with elevated serum LDH level (P=0.054 and P=0.880), with advanced Ann Arbor stage (P=0.075 and P=0.286), and with tumor Ki-67 over 80% (P=0.190 and P=0.109), when compared with those of patients without these risk factors. Conclusion: RCDOP can improve the therapeutic effect and prognosis of DLBCL patients with certain high risk factors, such as intermediate and high IPI risks, multiple extra-nodal involvements, bulky disease, age over 60, elevated LDH level, advanced Ann Arbor stage and tumor Ki-67 over 80%.

Molecular cloning and preliminary analysis of a fragile site associated gene / 生物医学与环境科学（英文）

<p><b>OBJECTIVE</b>To analyze the molecular coining of a fragile site-associated gene.</p><p><b>METHODS</b>Genomic Chinese hamster ovary (CHO) DNA library was constructed using high molecular weight CHO DNA partially digested with MboI restriction enzyme from cultured CHO cells. Screening of genomic DNA library followed the established procedures. Genomic CHO in the positive clones was sequenced. Appropriate primers were designed for the reverse transcriptase-polymerase chain reactions (RT-PCR). The RT-PCR products were cloned into a pCRII TOPO vector and confirmed by DNA sequencing. Antibodies were prepared using synthetic peptides as antigens by immunizing the rabbits. Immunohistochemical analyses were performed to evaluate the expression of the novel gene in different tissues.</p><p><b>RESULTS</b>To investigate the molecular mechanism underlying the initial events of mdr1a amplification, we cloned 1q31 fragile site DNA. Strikingly, we found that this fragile site contained a novel gene which was designated as a fragile site-associated (FSA) gene. FSA encoded an unusually large mRNA of approximately16 kb. Full-length human FSA cDNA was cloned. FSA mRNA was expressed in many cultured cells and tissue types. Immunohistochemical analyses also revealed an expression pattern of the encoded proteins in postmitotic, well-differentiated epithelial compartments of many organs, including colon, mammary glands, ovary, prostate, and bladder.</p><p><b>CONCLUSION</b>FSA plays an important role in regulating mammalian epithelial cell growth and differentiation.</p>